This study aimed to elucidate the potential of Homeobox A11 (HOXA11) as a
therapeutic target and a diagnostic methylation marker for cervical cancer. Gene
expression analysis using cDNA microarray in cervical cancer cell lines revealed
significantly reduced expression of the HOXA11 gene. Subsequent investigation of
HOXA11 promoter methylation in samples from normal individuals and invasive
cervical cancer patients showed over 53.2% higher methylation in cancer
scrapes compared to normal scrapes. Furthermore, overexpression of HOXA11, which
is downregulated in cervical cancer, strongly suppressed cell growth in cervical
cancer cell lines, HeLa and HT3. Additionally, we performed transferase dUTP
nick end labeling assay and confirmed that the inhibition of cervical cancer
cell proliferation occurred via apoptosis. Mechanistically, overexpression of
HOXA11 led to mitochondrial apoptosis characterized by PARP cleavage due to
increased c-Myc and enhanced cytochrome C secretion into the cytoplasm. These
findings suggest that HOXA11 could potentially serve as a methylation marker for
diagnosing cervical cancer and as a novel therapeutic target for its
treatment.